Fulcrum Therapeutics (FULC) Other Accumulated Expenses (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Other Accumulated Expenses of $174000.0 for Q2 2026, up 0.58% year-over-year from $173000.0 in Q2 2025, and down 43.51% quarter-over-quarter from $308000.0 in Q1 2026.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Other Accumulated Expenses (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Other Accumulated Expenses for 9 consecutive years, with $174000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Accumulated Expenses rose 0.58% year-over-year to $174000.0; the TTM figure through Jun 2026 stood at $174000.0 (up 0.58% YoY), while the FY2025 annual figure was $258000.0, down 44.28% from the prior year.
- Other Accumulated Expenses declined to $174000.0 in Q2 2026 per FULC's latest filing, from $308000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $463000.0 in Q4 2024 and bottomed at $9000.0 in Q1 2023.
- Historically, Other Accumulated Expenses has averaged $227944.4 across 5 years, with a median of $247000.0 in 2025.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses sank 93.28% — and 2024, when it soared 4177.78%.
- Fulcrum Therapeutics' Other Accumulated Expenses stood at $105000.0 in 2022, then soared by 277.14% to $396000.0 in 2023, then advanced by 16.92% to $463000.0 in 2024, then tumbled by 44.28% to $258000.0 in 2025, then tumbled by 32.56% to $174000.0 in 2026.
- Business Quant data shows FULC's Other Accumulated Expenses at $174000.0 in Q2 2026, $308000.0 in Q1 2026, and $258000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 174,000.00 |
| Mar 31, 2026 | 308,000.00 |
| Dec 31, 2025 | 258,000.00 |
| Sep 30, 2025 | 236,000.00 |
| Jun 30, 2025 | 173,000.00 |
| Mar 31, 2025 | 441,000.00 |
| Dec 31, 2024 | 463,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 306,000.00 |
| Mar 31, 2024 | 385,000.00 |
| Dec 31, 2023 | 396,000.00 |
| Sep 30, 2023 | 265,000.00 |
| Jun 30, 2023 | 14,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Dec 31, 2022 | 105,000.00 |
| Sep 30, 2022 | 25,000.00 |
| Jun 30, 2022 | 11,000.00 |
| Mar 31, 2022 | 134,000.00 |
| Dec 31, 2021 | 74,000.00 |
| Sep 30, 2021 | 57,000.00 |